Nitrofurantoin Mercury Pharmaceuticals Ltd (Nitrofurantoin Monohydrate)

The drug is reduced by bacterial enzymes to reactive intermediates that damage bacterial DNA, ribosomal proteins, and carbohydrate‑metabolizing enzymes. This multi‑target attack disrupts essential bacterial processes, leading to cell death, especially in urinary pathogens that achieve high concentrations in the urine.

The dosage regimen for Nitrofurantoin is determined by the prescribing clinician based on the infection severity, patient renal function, and local guidelines. Patients should follow the prescriber’s instructions and the product label.

Nitrofurantoin is classified as pregnancy category B, indicating no evidence of risk in animal studies but limited human data. It may be used during pregnancy only when clearly needed. Limited amounts are excreted in breast milk; breastfeeding decisions should be made with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other agents such as trimethoprim‑sulfamethoxazole, Nitrofurantoin has a narrow spectrum focused on common urinary pathogens and achieves high urinary concentrations, making it effective for uncomplicated infections while limiting systemic exposure. Resistance patterns and patient renal function guide the choice of therapy.

Nitrofurantoin tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep out of reach of children and do not use after the expiry date.

Nitrofurantoin is taken orally, usually with food or milk to reduce gastrointestinal irritation. The tablets should be swallowed whole with a full glass of water and not chewed or crushed unless specifically instructed by a healthcare professional.

Serious adverse events include pulmonary toxicity (interstitial lung disease or acute respiratory distress), severe hepatic injury, blood dyscrasias such as agranulocytosis or aplastic anaemia, peripheral neuropathy, and hemolytic anaemia in patients with G6PD deficiency. Prompt medical attention is required if these occur.

Nitrofurantoin is contraindicated in patients with severe renal impairment (creatinine clearance <60 mL/min), known hypersensitivity to the drug, and in those with a history of pulmonary toxicity from Nitrofurantoin. Caution is advised in pregnant women, the elderly, and patients with G6PD deficiency.